| # | Drug | Count |
|---|---|---|
| 0 | ETOPOSIDE | 21 |
| 1 | CARBOPLATIN | 20 |
| 2 | CYCLOPHOSPHAMIDE | 19 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 19 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 19 |
| 5 | DOXORUBICIN | 12 |
| 6 | CISPLATIN | 9 |
| 7 | THIOTEPA | 7 |
| 8 | TOPOTECAN | 6 |
| 9 | DOXORUBICIN HYDROCHLORIDE | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TOPOTECAN | 6 | 0.0010 |
| 1 | THIOTEPA | 7 | 0.0007 |
| 2 | TOPOTECAN HYDROCHLORIDE | 1 | 0.0004 |
| 3 | ETOPOSIDE | 21 | 0.0003 |
| 4 | CRIZOTINIB | 2 | 0.0002 |
| 5 | CARBOPLATIN | 20 | 0.0002 |
| 6 | DOXORUBICIN HYDROCHLORIDE | 5 | 0.0002 |
| 7 | DOXORUBICIN | 12 | 0.0001 |
| 8 | MESNA INJECTION | 1 | 0.0001 |
| 9 | MESNA | 1 | 0.0001 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 21 |
| 1 | Topoisomerase Inhibitor [EPC] | 21 |
| 2 | Alkylating Drug [EPC] | 20 |
| 3 | Kinase Inhibitor [EPC] | 5 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 2 |
| 5 | Angiotensin 2 Receptor Blocker [EPC] | 1 |
| 6 | Antifibrinolytic Agent [EPC] | 1 |
| 7 | HMG-CoA Reductase Inhibitor [EPC] | 1 |
| 8 | Leukocyte Growth Factor [EPC] | 1 |
| 9 | Progesterone [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Topoisomerase Inhibitor [EPC] | 21 | 0.0003 |
| 1 | Antifibrinolytic Agent [EPC] | 1 | 0.0001 |
| 2 | Alkylating Drug [EPC] | 20 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 21 | 0.0001 |
| 4 | Progesterone [EPC] | 1 | 0.0000 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1 | 0.0000 |
| 6 | Kinase Inhibitor [EPC] | 5 | 0.0000 |
| 7 | Serotonin-3 Receptor Antagonist [EPC] | 1 | 0.0000 |
| 8 | alpha-Adrenergic Blocker [EPC] | 1 | 0.0000 |
| 9 | Leukocyte Growth Factor [EPC] | 1 | 0.0000 |